Bayer donates 1.5 million euros for immediate aid to victims of devastating earthquakes in Türkiye and Syria
Bayer provides 1 million euros for immediate aid to Türkiye via the disaster relief organizations Red Crescent and Ahbap as well as 200.000 euros to Syria via the German Red Cross / A global employee donation campaign for both Türkiye and Syria will be matched by the company up to 300.000 euros via the German Red Cross / Paid volunteering hours are made available to qualified Bayer professionals in the region / Product donations are being prepared based on assessment of most urgent needs
Leverkusen, February 8, 2023 – After a massive earthquake hit southern Türkiye and northern Syria, Bayer has released immediate emergency funding of 1.5 million euros to support the population in the affected regions. A total amount of 500.000 euros will be donated to the Turkish humanitarian organization Ahbap and 500.000 euros to Kizilay (Red Crescent in Türkiye). Additionally, Bayer will donate 200.000 euros to the German Red Cross for disaster response in Syria.
“Our thoughts are with everyone who has been affected by this horrific natural disaster, including our colleagues, partners, and their families. We are grateful for every action that is being taken by governments, NGOs and rescue teams to help the victims in both countries”, says Werner Baumann, Bayer CEO.
Bayer has also launched an employee donation campaign with the German Red Cross and will match the funds donated by employees up to 300.000 euros. The final amount will benefit both Syria and Türkiye.
Bayer is also offering paid volunteering hours to qualified Bayer professionals in the region and preparing product donations – both of vital medicines and agricultural products – based on an assessment of the most urgent needs.
The Ahbap Association is a Turkish organization established with the aim of providing all kinds of assistance to people in need, strengthening the awareness of solidarity in society, creating modern and sustainable cooperation and solidarity networks with new cooperation models and projects, preserving the local culture and contributing to the development of today's technological opportunities and carrying it to the future.
About Kızılay (Red Crescent in Türkiye)
From the time of its establishment in 1868, the Turkish Red Crescent, besides contributing to the development of social welfare has been providing, presenting and offering various and important services for social solidarity such as shelter and protection to the poor and needy, aids for nourishment and health care , blood, disaster operations, international aids, social services, health, first aid, education and youth, housing, immigration and refugee protection as well as operating mineral water facilities.
About German Red Cross
The German Red Cross (DRK) is the national Red Cross Society in Germany according to the Geneva Conventions and as such part of the International Red Cross and Red Crescent Movement with headquarters in Berlin. The DRK rescues people, helps in emergencies, offers people a community, stands by the poor and needy, and watches over international humanitarian law - in Germany and around the world. The DRK has more than three million members.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.